HIGHLIGHTS
- who: Amin Izadpanah from the AdventHealth, United States Virginia Commonwealth University have published the paper: Targeting TRAF3IP2 inhibits angiogenesis in glioblastoma, in the Journal: (JOURNAL)
- what: Using a brain xenograft model, the authors demonstrate the critical role of TRAF3IP2 in driving GBM angiogenesis.
- how: The data were analyzed using Prism GraphPad 6 software (GraphPad Software Inc.).
- future: Future studies will assess the efficacy of targeting TRAF3IP2 as a monotherapy or a combination therapy in robust animal models of heterogeneous primary GBM with reductions in tumor size angiogenesis cerebral edema and improvements . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.